Imperial College London
Portrait Picture

DrJunIshihara

Faculty of Engineering, Department of Bioengineering

Lecturer
 
 
 
//

Contact

 

j.ishihara Website CV

 
 
//

Location

 

86 Woodlane London W12 0BZSir Michael Uren HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Williford:2019:10.1126/sciadv.aay1357,
author = {Williford, J-M and Ishihara, J and Ishihara, A and Mansurov, A and Hosseinchi, P and Marchell, TM and Potin, L and Swartz, MA and Hubbell, JA},
doi = {10.1126/sciadv.aay1357},
journal = {Science Advances},
pages = {1--15},
title = {Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy},
url = {http://dx.doi.org/10.1126/sciadv.aay1357},
volume = {5},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Although a clinical breakthrough for cancer treatment, it remains that a minority of patients respond to checkpoint inhibitor (CPI) immunotherapy. The composition of tumor-infiltrating immune cells has been identified as a key factor influencing CPI therapy success. Thus, enhancing tumor immune cell infiltration is a critical challenge. A lack of the chemokine CCL4 within the tumor microenvironment leads to the absence of CD103+ dendritic cells (DCs), a crucial cell population influencing CPI responsiveness. Here, we use a tumor stroma–targeting approach to deliver CCL4; by generating a fusion protein of CCL4 and the collagen-binding domain (CBD) of von Willebrand factor, we show that CBD fusion enhances CCL4 tumor localization. Intravenous CBD-CCL4 administration recruits CD103+ DCs and CD8+ T cells and improves the antitumor effect of CPI immunotherapy in multiple tumor models, including poor responders to CPI. Thus, CBD-CCL4 holds clinical translational potential by enhancing efficacy of CPI immunotherapy.
AU  - Williford,J-M
AU  - Ishihara,J
AU  - Ishihara,A
AU  - Mansurov,A
AU  - Hosseinchi,P
AU  - Marchell,TM
AU  - Potin,L
AU  - Swartz,MA
AU  - Hubbell,JA
DO  - 10.1126/sciadv.aay1357
EP  - 15
PY  - 2019///
SN  - 2375-2548
SP  - 1
TI  - Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy
T2  - Science Advances
UR  - http://dx.doi.org/10.1126/sciadv.aay1357
UR  - https://advances.sciencemag.org/content/5/12/eaay1357
UR  - http://hdl.handle.net/10044/1/83366
VL  - 5
ER  -
Download